Kymera Therapeutics Inc at Bank of America Biotech SMID Cap Conference Transcript
All right. Afternoon, everyone. My name is Geoff Meacham, I'm the Senior of Biopharma Analyst here at BofA, and welcome to the first day of our SMID Biotech Virtual Conference, and we're thrilled today to have Nello Mainolfi, who is CEO of Kymera Therapeutics. Nello, good to see you.
Thanks, Geoff. Thanks for the invite.
Yes, of course, yes. So before getting to questions, maybe you just want to give like a high-level overview and we can -- and go from there.
Yes. So welcome everybody. So the -- Kymera was founded about 6 years ago with the goal of taking a really powerful potentially transformative modality called targeted protein
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
